Outcome measures in pediatric AEL
| Variable . | n . | 5-y OS, % ± 2SE% . | 5-y EFS, % ± 2SE% . |
|---|---|---|---|
| Morphology | |||
| M0-M5, M7 FAB | 1910 | 65 ± 2* | 50 ± 2* |
| M6 FAB | 24 | 56 ± 21 | 41 ± 20 |
| PEL | 5 | 20 ± 36† | 20 ± 36† |
| Erythroid/myeloid leukemia | 19 | 66 ± 23* | 46 ± 23* |
| MDS (new WHO classification) | 10 | 56 ± 33 | 48 ± 33 |
| AML (new WHO classification) | 5 | 80 ± 36 | 40 ± 44 |
| Multilineage dysplasia | |||
| Absent | 16 | 48 ± 26 | 38 ± 24 |
| Present | 8 | 73 ± 33 | 50 ± 35 |
| Karyotype | |||
| Not complex | 17 | 55 ± 26 | 34 ± 24 |
| Complex | 7 | 57 ± 37 | 57 ± 37 |
| Mutations | |||
| WT1 wild type | 9 | 53 ± 35 | 56 ± 33 |
| WT1 mutation | 5 | 60 ± 44 | 20 ± 36 |
| TP53 wild type | 10 | 57 ± 23 | 40 ± 31 |
| TP53 mutation | 1 | 0 ± 0 | 0 ± 0‡ |
| Fusion status | |||
| No fusions | 13 | 45 ± 28 | 38 ± 27 |
| Fusion positive | 9 | 65 ± 33 | 30 ± 33 |
| NUP98 fusion positive | 7 | 54 ± 40 | 43 ± 37 |
| NUP98–KDM5A positive | 4 | 25 ± 43 | 25 ± 43 |
| NUP98–NSD1 positive | 2 | 100 ± 0 | NA |
| NUP98–SET positive | 1 | 100 ± 0 | 100 ± 0 |
| NPM1–MLF1 positive | 1 | NA | 0 ± 0 |
| RUNX1–MECOM positive | 1 | NA | 0 ± 0 |
| Morphology + fusion | |||
| PEL without NUP98 fusion | 2 | 0 ± 0 | 0 ± 0 |
| PEL with NUP98 fusion | 3 | 33 ± 54 | 33 ± 54 |
| PEL with NUP98–KDM5A fusion | 2 | 0 ± 0 | 0 ± 0 |
| MDS with NUP98 fusion | 3 | 50 ± 71 | 67 ± 54 |
| MDS with NUP98–KDM5A fusion | 2 | 50 ± 71 | 50 ± 71 |
| AML (nonerythroid) with NUP98–NSD1 fusion | 1 | 100 ± 0 | 0 ± 0 |
| Variable . | n . | 5-y OS, % ± 2SE% . | 5-y EFS, % ± 2SE% . |
|---|---|---|---|
| Morphology | |||
| M0-M5, M7 FAB | 1910 | 65 ± 2* | 50 ± 2* |
| M6 FAB | 24 | 56 ± 21 | 41 ± 20 |
| PEL | 5 | 20 ± 36† | 20 ± 36† |
| Erythroid/myeloid leukemia | 19 | 66 ± 23* | 46 ± 23* |
| MDS (new WHO classification) | 10 | 56 ± 33 | 48 ± 33 |
| AML (new WHO classification) | 5 | 80 ± 36 | 40 ± 44 |
| Multilineage dysplasia | |||
| Absent | 16 | 48 ± 26 | 38 ± 24 |
| Present | 8 | 73 ± 33 | 50 ± 35 |
| Karyotype | |||
| Not complex | 17 | 55 ± 26 | 34 ± 24 |
| Complex | 7 | 57 ± 37 | 57 ± 37 |
| Mutations | |||
| WT1 wild type | 9 | 53 ± 35 | 56 ± 33 |
| WT1 mutation | 5 | 60 ± 44 | 20 ± 36 |
| TP53 wild type | 10 | 57 ± 23 | 40 ± 31 |
| TP53 mutation | 1 | 0 ± 0 | 0 ± 0‡ |
| Fusion status | |||
| No fusions | 13 | 45 ± 28 | 38 ± 27 |
| Fusion positive | 9 | 65 ± 33 | 30 ± 33 |
| NUP98 fusion positive | 7 | 54 ± 40 | 43 ± 37 |
| NUP98–KDM5A positive | 4 | 25 ± 43 | 25 ± 43 |
| NUP98–NSD1 positive | 2 | 100 ± 0 | NA |
| NUP98–SET positive | 1 | 100 ± 0 | 100 ± 0 |
| NPM1–MLF1 positive | 1 | NA | 0 ± 0 |
| RUNX1–MECOM positive | 1 | NA | 0 ± 0 |
| Morphology + fusion | |||
| PEL without NUP98 fusion | 2 | 0 ± 0 | 0 ± 0 |
| PEL with NUP98 fusion | 3 | 33 ± 54 | 33 ± 54 |
| PEL with NUP98–KDM5A fusion | 2 | 0 ± 0 | 0 ± 0 |
| MDS with NUP98 fusion | 3 | 50 ± 71 | 67 ± 54 |
| MDS with NUP98–KDM5A fusion | 2 | 50 ± 71 | 50 ± 71 |
| AML (nonerythroid) with NUP98–NSD1 fusion | 1 | 100 ± 0 | 0 ± 0 |